基于游离DNA与联合筛查的早孕期筛查:女性体验的随机临床试验
这项单中心、开放标签、平行组随机临床试验将40名单胎妊娠孕妇随机分为早孕期联合筛查(FTCS)组或超声联合游离DNA(cfDNA)筛查组,比较两组的心理安抚、满意度和焦虑。cfDNA组在检测前和检测后问卷中的安抚评分均显著高于FTCS组,检测前满意度更高、状态特质焦虑量表(STAI)焦虑评分更低。
要点
- cfDNA组检测后安抚评分较FTCS组高16.50分(95%CI 2.18至30.82)。
- cfDNA组检测前安抚评分较FTCS组高0.80分(95%CI 0.27至1.33)。
- cfDNA组检测前满意度更高且STAI焦虑评分更低。
核心结论
- 与采用颈项透明层和生化指标的标准化早孕期联合筛查相比,详细超声检查联合cfDNA进行早孕期胎儿非整倍体风险评估与更好的母亲安抚和更高的母亲满意度相关。
研究设计与样本
- 单中心、开放标签、平行组、随机临床试验,共纳入40名单胎妊娠孕妇。
- 孕妇在首次产前检查时被随机分配至基于FTCS的早孕期风险评估策略组或基于超声所见和cfDNA的早孕期风险评估策略组。
- FTCS包括超声评估头臀长、颈项透明层(NT)测量和详细超声扫描,以及生化检查(PAPP-A和游离β-hCG)。
- 干预组接受基于超声所见和cfDNA的早孕期风险评估,cfDNA分析包括同时基于微阵列的非多态性位点(13、18、21、X和Y染色体)和多态性位点检测以估计染色体比例和胎儿分数。
- 主要结局为检测后安抚评分,定义为检测后安抚问卷的平均分;效应量以均数差(MD)及95%置信区间(CI)表示。
主要发现
- cfDNA组检测前安抚评分显著高于FTCS组(MD 0.80分,95%CI 0.27至1.33)。
- cfDNA组检测后安抚评分显著高于FTCS组(MD 16.50分,95%CI 2.18至30.82)。
- 随机分配至cfDNA组的女性检测前满意度更高,STAI检测前问卷评估的平均焦虑评分更低。
关键数值与推荐
- FTCS组:风险>1/100、NT>3.5 mm或超声发现任何胎儿异常者接受侵入性诊断检测。
- 干预组:cfDNA筛查结果异常、NT>3.5 mm或超声发现任何胎儿异常者接受侵入性诊断检测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare women's experience of first-trimester combined screening (FTCS), with women's experience of an approach that uses the combination of a detailed early anatomy scan and cell-free DNA (cfDNA) analysis. METHODS: This was single-center, open label, parallel group, randomized clinical trial. Pregnant women were randomized at the time of their first prenatal visit to either a policy of first-trimester risk assessment based on FTCS, or to a policy of first-trimester risk assessment based on ultrasound findings and cfDNA. FTCS included ultrasound evaluation with crown-rump length, nuchal translucency (NT) measurement, and a detailed ultrasound scan, along with biochemistry (PAPP-A and free beta hCG). In this group, invasive diagnostic testing was offered to patients with risk >1 in 100, or NT >3.5 mm, or any fetal abnormalities on ultrasound. Women randomized in the intervention group received an approach of first-trimester risk assessment based on ultrasound findings and cfDNA. cfDNA analysis included a simultaneous microarray-based assay of non-polymorphic (chromosomes 13, 18, 21, X and Y) and polymorphic loci to estimate chromosome proportion and fetal fraction. In the intervention group, invasive diagnostic testing was offered to patients with abnormal cfDNA screening results, or NT >3.5 mm, or any fetal abnormalities on ultrasound. Participants received pre-test and post-test questionnaires regarding to measure reassurance, satisfaction, and anxiety. The primary outcome was the post-test reassurance, defined as mean score of reassurance post-test questionnaire. The effect of the assigned screening test on the mean of each outcome was quantified as mean difference (MD) with 95% confidence interval (CI). RESULTS: Forty women with singleton gestations were enrolled in the trial. Mean score for reassurance was significantly higher in the cfDNA group compared to the FTCS group in the pre-test questionnaire (MD 0.80 points, 95% CI 0.27 to 1.33) and in the post-test questionnaire (MD 16.50 points, 95% CI 2.18 to 30.82). Women randomized to the cfDNA group had higher satisfaction and lower mean anxiety score as assessed in the STAI pre-test questionnaire. CONCLUSIONS: First-trimester risk assessment for fetal aneuploidy with a combination of a detailed ultrasound examination and cfDNA is associated with better maternal reassurance and better maternal satisfaction compared to the standard first-trimester combined screening with nuchal translucency, and biochemistry. TRIAL REGISTRATION: Clinicaltrials.gov NCT04077060.
引用
- Migliorini S, Saccone G, Silvestro F, et al. First-trimester screening based on cell-free DNA vs combined screening: A randomized clinical trial on women's experience. Prenat Diagn. 2020. PMID: 32683755. doi:10.1002/pd.5800
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。